|
|
|
LifeScienceHistory.com - Check us out on Instagram
New York Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing New YorkLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Retrophin, Inc.
| | | Phone: | (617) 500-7991 | Year Established: | 2011 | Ticker: | RTRX | Exchange: | NASDAQ | Main Contact: | Stephen Aselage, CEO | | Other Contacts: | Elizabeth Reed, General Counsel William "Bill" Rote, Ph.D., Senior VP, R&D Laura M. Clague, C.P.A., CFO Laura M. Clague, CPA, Senior VP & CFO Neil McFarlane, COO
| | Company Description | Retrophin is a biopharmaceutical company specializing in identifying, developing and delivering life- changing therapies to people living with rare diseases. The Company’s approach centers on its pipeline featuring late-stage assets targeting rare diseases with significant unmet medical needs, including fosmetpantotenate for pantothenate kinase-associated neurodegeneration (PKAN), a life-threatening neurological disorder that typically begins in early childhood, and sparsentan for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN), disorders characterized by progressive scarring of the kidney often leading to end-stage renal disease and glomerulonephritis, respectively. | |
|
|
|
|
|